• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Working Together towards the Longitudinal Cohort Study (LCS) Start-up!

2016-04-28News

 

The first quarter of 2016 started with great intensity! We were busy working towards recruiting the very first research participant into our study and should reach this important milestone early next month. A serious engagement of the entire EPAD family was also needed for the mandatory scientific and financial progress report to the Innovative Medicines Initiative.

Here are some of the team’s major achievements during the past period:

The operational aspects of the Longitudinal Cohort Study are now finalised

Next to the requirements for Good Clinical Practice (GCP) and ethical considerations, organising the study itself from an operational perspective takes time. The EPAD operations team has successfully established all required service contracts (clinical assessments, bio-banking etc.), coordinated local Ethics Committee submissions and prepared best practices for sample management.

Six trial delivery centres are now certified and staff trained and ready for action

On 21 March, site personnel from the first six certified EPAD Trial Delivery Centres (TDCs) were trained during the first EPAD Investigator Meeting in Edinburgh. Make sure to read the report of this meeting here: http://ep-ad.org/2016/03/21/epad-launches-largest-ever-pre-dementia-cohort/

Our communication strategy has been updated

A new year and ever-evolving project needs calls for a 2016 Communication Action Plan and that’s exactly what WP6 developed. Emphasis has been placed on generating awareness of the project itself and its expected results, rallying stakeholders as well as the general public around EPAD’s cause in order to create an EPAD community and educating the broader public about the fundamental concepts EPAD is built on.

Our first progress report has been submitted to the Innovative Medicines Initiative

With the first project year of EPAD completed, a first official annual report about the project scientific and financial progress of each individual partner and the consortium as a whole was submitted to IMI. Approval of this report is a prerequisite for future milestone payments to Beneficiary Partners in EPAD.

Four cohorts are now connected in the EPAD Register with five additional ones to follow shortly

An initial set of nine Parent Cohorts (PCs) have been selected for inclusion in the Register, of which four are already connected to the ‘Participant Register for EPAD’ (PREPAD) software tool, and hence the present day Register encompasses >4000 potential research participants without dementia. The other five PCs will be incorporated in the next few months. In total, 23 PCs have been fingerprinted, representing >500,000 research participants.

Sound ethical recommendations will guide the next steps of the EPAD project

The EPAD ethics team (WP8) created an extensive recommendations document that tackles topics in the following areas:

  • Informed consent through the EPAD journey
  • Return of results and disclosure of Alzheimer’s risk
  • Incidental findings
  • The experience of participation in EPAD
  • Data sharing and governance
  • Continuity between the Longitudinal Cohort Study and the Proof-of-Concept (PoC) Studies

About EPAD

EPAD aims to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD will establish a European-wide cohort of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
2021-04-06
AD Workbench
The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
2021-03-18
EPAD_WordCloud
EPAD releases its first data and sample access bulletin
2021-03-10
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.